CA3233346A1 - Celiac disease epitopes - Google Patents

Celiac disease epitopes Download PDF

Info

Publication number
CA3233346A1
CA3233346A1 CA3233346A CA3233346A CA3233346A1 CA 3233346 A1 CA3233346 A1 CA 3233346A1 CA 3233346 A CA3233346 A CA 3233346A CA 3233346 A CA3233346 A CA 3233346A CA 3233346 A1 CA3233346 A1 CA 3233346A1
Authority
CA
Canada
Prior art keywords
peptide
seq
peptides
epitope
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233346A
Other languages
English (en)
French (fr)
Inventor
Geir Age Loset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nextera AS
Original Assignee
Nextera AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextera AS filed Critical Nextera AS
Publication of CA3233346A1 publication Critical patent/CA3233346A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3233346A 2021-09-28 2022-09-28 Celiac disease epitopes Pending CA3233346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2113858.1A GB202113858D0 (en) 2021-09-28 2021-09-28 Peptides
GB2113858.1 2021-09-28
PCT/GB2022/052450 WO2023052759A1 (en) 2021-09-28 2022-09-28 Celiac disease epitopes

Publications (1)

Publication Number Publication Date
CA3233346A1 true CA3233346A1 (en) 2023-04-06

Family

ID=78399559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233346A Pending CA3233346A1 (en) 2021-09-28 2022-09-28 Celiac disease epitopes

Country Status (6)

Country Link
US (1) US20240400692A1 (https=)
EP (1) EP4408539A1 (https=)
JP (1) JP2024538595A (https=)
CA (1) CA3233346A1 (https=)
GB (1) GB202113858D0 (https=)
WO (1) WO2023052759A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
JP7420330B2 (ja) * 2019-06-13 2024-01-23 学校法人藤田学園 アレルギーの抗原およびそのエピトープ
JP2023500799A (ja) * 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Ｃａｌ－ｔコンストラクトおよびその使用

Also Published As

Publication number Publication date
GB202113858D0 (en) 2021-11-10
WO2023052759A1 (en) 2023-04-06
JP2024538595A (ja) 2024-10-23
US20240400692A1 (en) 2024-12-05
EP4408539A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
Mézière et al. In vivo T helper cell response to retro-inverso peptidomimetics
CN110392695B (zh) 针对cd127的抗体和多肽
US9718870B2 (en) OX40L fusion proteins and uses thereof
US20140170168A1 (en) Antibodies which bind soluble t-cell receptor ligands
TW201718632A (zh) Ｇｉｔｒｌ融合蛋白及其用途
US12606626B2 (en) Antigen binding proteins which bind to the pMHC HLA-DQ2.5:DQ2.5 presenting a gliadin peptide
WO2004044001A2 (en) Acetylated hmgb1 protein
PT1835937E (pt) Composições e métodos para tratar infeção viral
US20170232083A1 (en) Methods of diagnosis and treatment of celiac disease in children
JP2013535963A (ja) Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
WO2016141334A2 (en) Compositions and methods for diagnosing and treating autoimmune diseases
US9657070B2 (en) Recombinant allergen
CN111138521B (zh) 源自于afp抗原的短肽
CN116514974A (zh) 抗cd28抗体及其应用
US20240400692A1 (en) Celiac disease epitopes
US12226449B2 (en) Materials and methods for the prevention of rheumatoid arthritis
CN111138522B (zh) 衍生自afp的肿瘤抗原短肽
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
WO2025140345A1 (zh) 一种tigit多肽及tigit/ctla4融合蛋白
CN110862449B (zh) 衍生自ssx的肿瘤抗原短肽
JP2026505826A (ja) 抗ｍａｇｅ－ａ４ ｔ細胞受容体
WO2024133573A1 (en) Antigen binding proteins
WO2024133584A2 (en) Antigen binding proteins
CN115490767A (zh) 一种识别afp抗原的tcr及其编码序列
WO2021035446A1 (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919